|
1
|
Peck WA: Consensus development conference:
Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med.
94:646–650. 1993. View Article : Google Scholar
|
|
2
|
Warrell RP Jr, Bockman RS, Coonley CJ,
Isaacs M and Staszewski H: Gallium nitrate inhibits calcium
resorption from bone and is effective treatment for cancer-related
hypercalcemia. J Clin Invest. 73:1487–1490. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Warrell RP Jr, Skelos A, Alcock NW and
Bockman RS: Gallium nitrate for acute treatment of cancer-related
hypercalcemia: Clinicopharmacological and dose response analysis.
Cancer Res. 46:4208–4212. 1986.PubMed/NCBI
|
|
4
|
Warrell RP Jr, Israel R, Frisone M, Snyder
T, Gaynor JJ and Bockman RS: Gallium nitrate for acute treatment of
cancer-related hypercalcemia. A randomized, double-blind comparison
to calcitonin. Ann Intern Med. 108:669–674. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Warrell RP Jr: Gallium nitrate for the
treatment of bone metastases. Cancer. 80(Suppl): 1680–1685. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Warrell RP Jr, Bosco B, Weinerman S,
Levine B, Lane J and Bockman RS: Gallium nitrate for advanced Paget
disease of bone: Effectiveness and dose-response analysis. Ann
Intern Med. 113:847–851. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niesvizky R: Gallium nitrate in multiple
myeloma: Prolonged survival in a cohort of patients with
advanced-stage disease. Semin Oncol. 30(Suppl 5): 20–24. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li C, Jiang Z and Liu X: Biochemical
mechanism of gallium on prevention of fatal cage-layer
osteoporosis. Biol Trace Elem Res. 134:195–202. 2010. View Article : Google Scholar
|
|
9
|
Chen X and Wang C: Activity of gallium on
prevention of fatal cage-layer osteoporosis. Biol Trace Elem Res.
132:129–135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Foster BJ, Clagett-Carr K, Hoth D and
Leyland-Jones B: Gallium nitrate: The second metal with clinical
activity. Cancer Treat Rep. 70:1311–1319. 1986.PubMed/NCBI
|
|
11
|
Simonet WS, Lacey DL, Dunstan CR, Kelley
M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et
al: Osteoprotegerin: A novel secreted protein involved in the
regulation of bone density. Cell. 89:309–319. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Teitelbaum SL: Osteoclasts, integrins, and
osteoporosis. J Bone Miner Metab. 18:344–349. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Theoleyre S, Wittrant Y, Tat SK, Fortun Y,
Redini F and Heymann D: The molecular triad OPG/RANK/RANKL:
Involvement in the orchestration of pathophysiological bone
remodeling. Cytokine Growth Factor Rev. 15:457–475. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
ICLA recommendations for the specification
of the animals, the husbandry, and the techniques used in animal
experimentation. International Committee on Laboratory Animals -
Secretariat. Anat Anz. 145:413–414. 1979.
|
|
15
|
Liss B: Improved quantitative real-time
RT-PCR for expression profiling of individual cells. Nucleic Acids
Res. 30e892002.
|
|
16
|
Ma Z and Fu Q: Therapeutic effect of
organic gallium on ovariectomized osteopenic rats by decreased
serum minerals and increased bone mineral content. Biol Trace Elem
Res. 133:342–349. 2010. View Article : Google Scholar
|
|
17
|
Goodfellow LR, Earl S, Cooper C and Harvey
NC: Maternal diet, behaviour and offspring skeletal health. Int J
Environ Res Public Health. 7:1760–1772. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanis JA and McCloskey EV: Epidemiology of
vertebral osteoporosis. Bone. 13(Suppl 2): S1–S10. 1992.PubMed/NCBI
|
|
19
|
Melton LJ III, Lane AW, Cooper C, Eastell
R, O'Fallon WM and Riggs BL: Prevalence and incidence of vertebral
deformities. Osteoporos Int. 3:113–119. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
van Staa TP, Dennison EM, Leufkens HG and
Cooper C: Epidemiology of fractures in England and Wales. Bone.
29:517–522. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Van der Klift M, De Laet CE, McCloskey EV,
Hofman A and Pols HA: The incidence of vertebral fractures in men
and women: The Rotterdam Study. J Bone Miner Res. 17:1051–1056.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Felsenberg D, Silman AJ, Lunt M, Armbrecht
G, Ismail AA, Finn JD, Cockerill WC, Banzer D, Benevolenskaya LI,
Bhalla A, et al European Prospective Osteoporosis Study (EPOS)
Group: Incidence of vertebral fracture in europe: Results from the
European Prospective Osteoporosis Study (EPOS). J Bone Miner Res.
17:716–724. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lord SR: Hip fractures: Changing patterns
in hospital bed use in NSW between 1979 and 1990. Aust N Z J Surg.
63:352–355. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Repo MA, Bockman RS, Betts F, Boskey AL,
Alcock NW and Warrell RP Jr: Effect of gallium on bone mineral
properties. Calcif Tissue Int. 43:300–306. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bockman RS, Boskey AL, Blumenthal NC,
Alcock NW and Warrell RP Jr: Gallium increases bone calcium and
crystallite perfection of hydroxyapatite. Calcif Tissue Int.
39:376–381. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bockman RS, Boskey AL, Blumenthal NC,
Alcock NW and Warrell RP Jr: Gallium increases bone calcium and
crystallite perfection of hydroxyapatite. Calcif Tissue Int.
39:376–381. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma Z and Fu Q: Comparison of the
therapeutic effects of yeast-incorporated gallium with those of
inorganic gallium on ovariectomized osteopenic rats. Biol Trace
Elem Res. 134:280–287. 2010. View Article : Google Scholar
|
|
28
|
Pei Y and Fu Q: Yeast-incorporated gallium
promotes fracture healing by increasing callus bony area and
improving trabecular microstructure on ovariectomized osteopenic
rats. Biol Trace Elem Res. 141:207–215. 2011. View Article : Google Scholar
|
|
29
|
Bedikian AY, Valdivieso M, Bodey GP,
Burgess MA, Benjamin RS, Hall S and Freireich EJ: Phase I clinical
studies with gallium nitrate. Cancer Treat Rep. 62:1449–1453.
1978.PubMed/NCBI
|
|
30
|
Krakoff IH, Newman RA and Goldberg RS:
Clinical toxicologic and pharmacologic studies of gallium nitrate.
Cancer. 44:1722–1727. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu J, Zhang B, He X, Zhang P and Chai Z:
Selection of a high-biomass, chromium-rich yeast strain and
optimization of cultivation conditions. J Ind Microbiol Biotechnol.
27:195–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Han C, Yuan J, Wang Y and Li L:
Hypoglycemic activity of fermented mushroom of Coprinus comatus
rich in vanadium. J Trace Elem Med Biol. 20:191–196. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Han C, Cui B and Wang Y: Vanadium uptake
by biomass of Coprinus comatus and their effect on hyperglycemic
mice. Biol Trace Elem Res. 124:35–39. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Verron E, Masson M, Khoshniat S, Duplomb
L, Wittrant Y, Baud'huin M, Badran Z, Bujoli B, Janvier P, Scimeca
JC, et al: Gallium modulates osteoclastic bone resorption in vitro
without affecting osteoblasts. Br J Pharmacol. 159:1681–1692. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yasuda H, Shima N, Nakagawa N, Yamaguchi
K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A,
et al: Osteoclast differentiation factor is a ligand for
osteopro-tegerin/osteoclastogenesis-inhibitory factor and is
identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 95:3597–3602.
1998. View Article : Google Scholar
|
|
36
|
Lacey DL, Timms E, Tan HL, Kelley MJ,
Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S,
et al: Osteoprotegerin ligand is a cytokine that regulates
osteoclast differentiation and activation. Cell. 93:165–176. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Anderson DM, Maraskovsky E, Billingsley
WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D
and Galibert L: A homologue of the TNF receptor and its ligand
enhance T-cell growth and dendritic-cell function. Nature.
390:175–179. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wong BR, Rho J, Arron J, Robinson E,
Orlinick J, Chao M, Kalachikov S, Cayani E, Bartlett FS III,
Frankel WN, et al: TRANCE is a novel ligand of the tumor necrosis
factor receptor family that activates c-Jun N-terminal kinase in T
cells. J Biol Chem. 272:25190–25194. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
American Society for Bone and Mineral
Research President's Committee on Nomenclature: Proposed standard
nomenclature for new tumor necrosis factor family members involved
in the regulation of bone resorption. J Bone Miner Res.
15:2293–2296. 2000. View Article : Google Scholar
|
|
40
|
Li Y, Toraldo G, Li A, Yang X, Zhang H,
Qian WP and Weitzmann MN: B cells and T cells are critical for the
preservation of bone homeostasis and attainment of peak bone mass
in vivo. Blood. 109:3839–3848. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hofbauer LC and Schoppet M: Clinical
implications of the osteoprotegerin/RANKL/RANK system for bone and
vascular diseases. JAMA. 292:490–495. 2004. View Article : Google Scholar : PubMed/NCBI
|
